Benzgalantamine gluconate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for benzgalantamine gluconate and what is the scope of freedom to operate?
Benzgalantamine gluconate
is the generic ingredient in one branded drug marketed by Alpha Cognition and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Benzgalantamine gluconate has twenty-four patent family members in seventeen countries.
One supplier is listed for this compound.
Summary for benzgalantamine gluconate
| International Patents: | 24 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | benzgalantamine gluconate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for benzgalantamine gluconate
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for benzgalantamine gluconate
US Patents and Regulatory Information for benzgalantamine gluconate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for benzgalantamine gluconate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2022150917 | ⤷ Sign Up | |
| Denmark | 1940817 | ⤷ Sign Up | |
| European Patent Office | 1777222 | Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs (Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment) | ⤷ Sign Up |
| China | 116761612 | α-1062葡糖酸盐的固体形式 (Solid forms of alpha-1062 gluconate) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
